SLC5A2 and type 2 diabetes mellitus: According to the safety profiles, SGLT2 inhibitors do not appear to reduce monocyte counts in humans with T2DM, suggesting that the effects of SGLT2 inhibitors on monocytosis in diabetic mice might not be translated to humans.